The KAT2B antibody targets the lysine acetyltransferase 2B (KAT2B), also known as PCAF (p300/CBP-associated factor), a key enzyme involved in epigenetic regulation. KAT2B belongs to the GNAT (Gcn5-related N-acetyltransferase) family and functions as a histone acetyltransferase, modifying histones by transferring acetyl groups to specific lysine residues. This activity promotes chromatin relaxation, facilitating transcriptional activation. Beyond histones, KAT2B acetylates non-histone proteins, including transcription factors (e.g., p53. Myc) and metabolic enzymes, thereby influencing diverse cellular processes like cell cycle progression, differentiation, and DNA repair.
KAT2B antibodies are widely used in research to study its expression, localization, and functional roles in both normal physiology and disease. Dysregulation of KAT2B has been linked to cancers, neurodegenerative disorders, and metabolic syndromes. For example, its overexpression in certain tumors correlates with enhanced oncogenic signaling, while reduced activity is implicated in cognitive deficits. These antibodies are critical tools in techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP), enabling researchers to map KAT2B’s interactions and regulatory networks.
Commercial KAT2B antibodies are typically validated for specificity and sensitivity, with applications spanning basic molecular biology and translational studies. Understanding KAT2B’s mechanisms through such reagents may aid in developing therapies targeting epigenetic pathways or acetyltransferase-related diseases.